Akouos, Inc. is a wholly owned subsidiary of Eli Lilly and Company. Over the coming months, you will see Akouos adopting the Lilly name and logo.
We focus on developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people with hearing loss.
Our Clinical Trial for AK-antiVEGF:
The purpose of this trial is to evaluate whether the study drug, administered once using the study device, is safe at different dose levels. Researchers in this trial will also evaluate whether the study drug is able to stabilize or improve hearing and/or shrink the size of the tumor in individuals affected by unilateral vestibular schwannoma.
For more information about our clinical trial and surgical administration procedure:
